KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $118,000.

  • Aquestive Therapeutics' Change in Accured Expenses rose 117.82% to $118,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 21.46%. This contributed to the annual value of -$1.5 million for FY2024, which is 40.68% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Change in Accured Expenses stood at $118,000 for Q3 2025, which was down 80.33% from $600,000 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Change in Accured Expenses registered a high of $1.9 million during Q2 2022, and its lowest value of -$4.0 million during Q1 2022.
  • Its 3-year average for Change in Accured Expenses is -$551,364, with a median of $118,000 in 2025.
  • Examining YoY changes over the last 5 years, Aquestive Therapeutics' Change in Accured Expenses showed a top increase of 3,916.00% in 2023 and a maximum decrease of 160.30% in 2023.
  • Aquestive Therapeutics' Change in Accured Expenses (Quarterly) stood at $1.2 million in 2021, then tumbled by 102.08% to -$25,000 in 2022, then soared by 3,916.00% to $954,000 in 2023, then fell by 3.98% to $916,000 in 2024, then surged by 117.82% to $118,000 in 2025.
  • Its last three reported values are $118,000 in Q3 2025, $600,000 for Q2 2025, and -$2.8 million during Q1 2025.